13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001583977
Total reported value
$2.0B
$2.0B
45 檔
42.6%
At the close of Q3 2024, Cormorant Asset Management, LP disclosed equity holdings valued at approximately $2.0B, spread across 45 reported holdings.
In Q3 2024, Cormorant Asset Management, LP adopted a defensive or profit-taking posture, trimming 11 positions and completely liquidating 8 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 22.71% | -0.99% | — | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 6.06% | -0.14% | -9.09% | |
| 3 | ACLXGBX | Arcellx Inc | Stock-Other | 5.54% | — | -18.03% | |
| 4 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 4.93% | — | — | |
| 5 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.82% | +0.07% | +13.30% | |
| 6 | EYPT | Eyepoint Inc | Stock-Other | 3.53% | -0.22% | — | |
| 7 | RAPP | Rapport Therapeutics Inc | Stock-Other | 3.19% | +1.02% | +0.02% | |
| 8 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.98% | -0.22% | -18.52% | |
| 9 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.65% | -3.35% | +27.01% | |
| 10 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.60% | +0.02% | +17.28% | |
| 11 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.56% | — | +147.06% | |
| 12 | JANX | Janux Therapeutics Inc | Stock-Other | 2.53% | — | — | |
| 13 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.51% | -1.07% | — | |
| 14 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.17% | -0.66% | +7.39% | |
| 15 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.17% | -2.09% | EXIT | |
| 16 | ✓ | Merus N V | Stock-Other | 1.96% | — | -11.90% | |
| 17 | CGON | Cg Oncology Inc | Stock-Other | 1.95% | — | — | |
| 18 | INSM | Insmed Inc | Stock-Healthcare | 1.94% | -1.15% | -25.93% | |
| 19 | BMEA | Biomea Fusion Inc | Stock-Other | 1.91% | — | — | |
| 20 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.91% | -0.42% | EXIT | |
| 21 | BIOA | Bioage Labs Inc | Stock-Other | 1.80% | +0.46% | — | |
| 22 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.61% | — | — | |
| 23 | PHVS | Pharvaris N.V. | Stock-Other | 1.44% | -0.09% | — | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 1.30% | +0.36% | — | |
| 25 | ALMS | Alumis Inc | Stock-Other | 1.22% | +0.37% | -0.00% | |
| 26 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.16% | — | — | |
| 27 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.15% | -0.29% | -7.92% | |
| 28 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.11% | — | -15.79% | |
| 29 | BHVN | Biohaven Ltd. | Stock-Other | 1.07% | +1.24% | -49.88% | |
| 30 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.04% | — | -6.06% | |
| 31 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 1.01% | — | — | |
| 32 | MBX | Mbx Biosciences Inc | Stock-Other | 0.96% | -0.12% | — | |
| 33 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.87% | -0.47% | — | |
| 34 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.73% | — | +13.68% | |
| 35 | ANAB | Anaptysbio Inc | Stock-Other | 0.61% | — | — | |
| 36 | KRRO | Korro Bio Inc | Stock-Other | 0.47% | — | — | |
| 37 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.39% | — | -36.00% | |
| 38 | ✓ | Engene Holdings Inc | Stock-Other | 0.35% | — | — | |
| 39 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 40 | NGNE | Neurogene Inc | Stock-Other | 0.24% | — | — | |
| 41 | GHRS | GH Research PLC | Stock-Other | 0.21% | — | — | |
| 42 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 43 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 44 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.08% | — | — | |
| 45 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.05% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BIOA | Bioage Labs Inc | +1.8% | NEW | New buy |
| 2 | EWTX | Edgewise Therapeutics Inc | +1.7% | +13.30% | Add |
| 3 | RNAGBP | Avidity Biosciences Inc | +1.6% | +147.06% | Add |
| 4 | 260 | Centessa Pharmaceuticals-adr | +1.3% | +58.95% | Add |
| 5 | PCVX | Vaxcyte Inc | +1.3% | -9.09% | Trim |
| 6 | MLTX | Moonlake Immunotherapeutics | +1.1% | — | Unchanged |
| 7 | PRAX | Praxis Precision Medicines I | +1% | +27.01% | Add |
| 8 | BMEA | Biomea Fusion Inc | +1% | — | Unchanged |
| 9 | MBX | Mbx Biosciences Inc | +1% | NEW | New buy |
| 10 | ACLXGBX | Arcellx Inc | +0.7% | -18.03% | Trim |
| 11 | ANAB | Anaptysbio Inc | +0.6% | NEW | New buy |
| 12 | ✓ | Longboard Pharmaceuticals In | +0.6% | — | Unchanged |
| 13 | AVBP | Arrivent Biopharma Inc | +0.2% | +13.68% | Add |
| 14 | CGON | Cg Oncology Inc | +0.2% | — | Unchanged |
| 15 | TARS | Tarsus Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 16 | ARTV | Artiva Biotherapeutics Inc | +0.1% | NEW | New buy |
| 17 | AXSM | Axsome Therapeutics Inc | +0.1% | — | Unchanged |
| 18 | CRGX | Cargo Therapeutics Inc | 0% | — | Unchanged |
| 19 | NGNE | Neurogene Inc | 0% | — | Unchanged |
| 20 | YMABUSD | Y-mabs Therapeutics Inc | — | — | Unchanged |
| 21 | JANX | Janux Therapeutics Inc | 0% | — | Unchanged |
| 22 | ✓ | Verve Therapeutics Inc | 0% | — | Unchanged |
| 23 | RYTM | Rhythm Pharmaceuticals Inc | 0% | -15.79% | Trim |
| 24 | VYNE | Vyne Therapeutics Inc | 0% | — | Unchanged |
| 25 | ✓ | Rapt Therapeutics Inc | 0% | — | Unchanged |
| 26 | STOK | Stoke Therapeutics Inc | -0.1% | — | Unchanged |
| 27 | KRRO | Korro Bio Inc | -0.1% | — | Unchanged |
| 28 | ✓ | Helix Acquisition CORP Ii | -0.1% | — | Unchanged |
| 29 | CMPX | Compass Therapeutics Inc | -0.1% | EXIT | Sold out |
| 30 | PHVS | Pharvaris N.V. | -0.2% | — | Unchanged |
| 31 | GHRS | GH Research PLC | -0.2% | — | Unchanged |
| 32 | ✓ | Engene Holdings Inc | -0.2% | — | Unchanged |
| 33 | ARQT | Arcutis Biotherapeutics Inc | -0.2% | -7.92% | Trim |
| 34 | BBIO | Bridgebio Pharma Inc | -0.2% | — | Unchanged |
| 35 | SIGA | Siga Technologies Inc | -0.2% | EXIT | Sold out |
| 36 | ✓ | Mersana Therapeutics Inc | -0.3% | EXIT | Sold out |
| 37 | SLN | Silence Therapeutics Plc-adr | -0.3% | -36.00% | Trim |
| 38 | ABVX | Abivax Sa-adr | -0.3% | — | Unchanged |
| 39 | LNTH | Lantheus Holdings Inc | -0.4% | EXIT | Sold out |
| 40 | NAMS | NewAmsterdam Pharma Company N.V. | -0.4% | +7.39% | Add |
| 41 | ALMS | Alumis Inc | -0.4% | -0.00% | Trim |
| 42 | IBRX | Immunitybio Inc | -0.5% | EXIT | Sold out |
| 43 | IDYA | Ideaya Biosciences Inc | -0.5% | EXIT | Sold out |
| 44 | CRNX | Crinetics Pharmaceuticals In | -0.5% | -18.52% | Trim |
| 45 | BHVN | Biohaven Ltd. | -0.5% | -49.88% | Trim |
| 46 | URGN | UroGen Pharma Ltd. | -0.6% | -6.06% | Trim |
| 47 | EYPT | Eyepoint Inc | -0.7% | — | Unchanged |
| 48 | INSM | Insmed Inc | -0.7% | -25.93% | Trim |
| 49 | RAPP | Rapport Therapeutics Inc | -0.8% | +0.02% | Add |
| 50 | ✓ | Merus N V | -0.9% | -11.90% | Trim |
According to official SEC Form 13F filings, Cormorant Asset Management, LP reported a total U.S. public equity portfolio value of $2.0B across 45 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MLTX, PCVX, ACLXGBX) accounted for 42.6% of total reported equity market value during Q3 2024.
Top New Position Initiated
BIOA
市值: $33.9M
Top Position Liquidated / Trimmed
SRPT
前期市值: $19.8M
During Q3 2024, Cormorant Asset Management, LP's top holdings by market value included MLTX (22.7%)、PCVX (6.1%)、ACLXGBX (5.5%). The largest single position, MLTX, represented 22.7% of total portfolio value.
In Q3 2024, Cormorant Asset Management, LP made 31 total portfolio adjustments, initiating 4 new buys, adding to 8 positions, trimming 11 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.